Top

Clinical and Translational Oncology

Published in:

01-06-2020 | Melanoma | Research Article

Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma

Authors: F. Consoli, M. Bersanelli, G. Perego, S. Grisanti, B. Merelli, A. Berruti, F. Petrelli

Published in: Clinical and Translational Oncology | Issue 6/2020

Abstract

Backgroud

Synergistic combinations between BRAF and MEK inhibitors, such as dabrafenib plus trametinib, vemurafenib plus cobimetinib or encorafenib plus binimetinib, represent the current standard of care in metastatic or locally advanced BRAF V600 mutated malignant melanomas (MM). However, no studies explored the direct head-to-head comparison between the three different combinations. In this paper, we performed a network meta-analysis to evaluate their efficacy in terms of overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and safety profile.

Method

We performed a systematic review of the literature about published first line trials of BRAF and MEK inhibitors doublets in advanced mutated malignant melanoma. We compared then the results with an adjusted indirect analysis of randomized-controlled trials. Our primary survival outcome was OS. Secondary endpoints were PFS, ORR, G3-4 toxicities described in at least 5% of patients in experimental arms.

Results

We identified three phase-3 trials: coBRIM (vemurafenib and cobimetinib), COMBI-v (dabrafenib and trametinib) and Columbus study (encorafenib and binimetinib) for a total of 1230 included patients. The control arm was vemurafenib in all studies. The indirect comparison revealed no statistically differences for OS, PFS and ORR across trials, while safety profile differed between the three couples of agents.

Conclusion

This indirect adjusted meta-analysis suggests a similar efficacy and a slightly different safety profile, related to specific molecular properties of the three different BRAF and MEK inhibitors currently approved in the management of advanced MM.

Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, et al. Survival of research involving human participants and/or animals with advanced metastatic melanoma: the impact of the novel therapies: update 2017. Eur J Cancer. 2017;83:247–57. https://doi.org/10.1016/j.ejca.2017.06.028.CrossRefPubMed

Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Classifying braf alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018;37(24):3183–99. https://doi.org/10.1038/s41388-018-0171-x.CrossRefPubMed

Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol. 2018;31(1):24–38. https://doi.org/10.1038/modpathol.2017.104.CrossRefPubMed

Eggermont AM, Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer. 2011;47(14):2150–7. https://doi.org/10.1016/j.ejca.2011.06.052.CrossRefPubMed

Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16. https://doi.org/10.1056/NEJMoa1103782.CrossRefPubMedPubMedCentral

Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open–label, phase 3 randomized controlled trial. Lancet. 2012;380(9839):358–65. https://doi.org/10.1016/S0140-6736(12)60868-X.CrossRefPubMed

Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, et al. Vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15(4):436–44. https://doi.org/10.1016/S1470-2045(14)70051-8.CrossRefPubMed

McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–32. https://doi.org/10.1016/S1470-2045(14)70012-9.CrossRefPubMedPubMedCentral

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–88. https://doi.org/10.1056/NEJMoa1406037.CrossRefPubMed

10.

Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. Ras mutations in cutaneous squamous-cell carcinoma in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207–15. https://doi.org/10.1056/NEJMoa1105358.CrossRefPubMedPubMedCentral

11.

Robert C, Karaszewska B, Schachter J, et al. Improved Overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–9. https://doi.org/10.1056/NEJMoa1412690.CrossRefPubMed

12.

Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–60. https://doi.org/10.1016/S1470-2045(16)30122-X.CrossRefPubMed

13.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(10):1315–27. https://doi.org/10.1016/S1470-2045(18)30497-2.CrossRefPubMed

14.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–15. https://doi.org/10.1016/S1470-2045(18)30142-6.CrossRefPubMed

15.

Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, et al. Three-year pooled analysis of factors associated with clinical outcome across dabrafenib and trametinib combination therapy phase 3 randomized trials. Eur J Cancer. 2017;82:45–55. https://doi.org/10.1016/j.ejca.2017.05.033.CrossRefPubMed

16.

Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–91. https://doi.org/10.1016/S0895-4356(97)00049-8.CrossRefPubMed

17.

Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. Lancet. 2018;392(10151):971–84. https://doi.org/10.1016/S0140-6736(18)31559-9.CrossRefPubMed

18.

Karoulia Z, Gavathiotis E, Poulikakos PI. New perspectives for targeting RAF kinase in human cancer. Nat Rev Cancer. 2017;17(11):676–91. https://doi.org/10.1038/nrc.2017.79.CrossRefPubMedPubMedCentral

19.

Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464(7287):431–5. https://doi.org/10.1038/nature08833.CrossRefPubMed

20.

Daud A, Gill J, Kamra S, Chen L, Ahuja A. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. J Hematol Oncol. 2017;10(1):3. https://doi.org/10.1186/s13045-016-0369-8.CrossRefPubMedPubMedCentral

21.

Sun J, Zager JS, Eroglu Z. Encorafenib/binimetinib for the treatment of BRAF mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy. Onco Target Ther. 2018;2018(11):9081–9. https://doi.org/10.2147/OTT.S171693.eCollection.CrossRef

22.

Koelblinger P, Thuerigen O, Dummer R. Development of encorafenib for BRAF-mutated advanced melanoma. Curre Opin Oncol. 2018;30(2):125–33. https://doi.org/10.1097/CCO.0000000000000426.CrossRef

23.

Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, et al. Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma. Clin Cancer Res. 2017;23(18):5339–488. https://doi.org/10.1158/1078-0432.CCR-16-2923.CrossRefPubMed

24.

Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427–30. https://doi.org/10.1038/nature08902.CrossRefPubMedPubMedCentral

25.

King AJ, Arnone MR, Bleam MR, Moss KG, Yang J, Fedorowicz KE, et al. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLoS ONE. 2013;8(7):e67583. https://doi.org/10.1371/journal.pone.0067583.CrossRefPubMedPubMedCentral

26.

Adelmann CH, Ching G, Du L, Saporito RC, Bansal V, Pence LJ, et al. Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity. Oncotarget. 2016;7(21):30453–60. https://doi.org/10.18632/oncotarget.8351.CrossRefPubMedPubMedCentral

Title: Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma
Authors: F. Consoli
M. Bersanelli
G. Perego
S. Grisanti
B. Merelli
A. Berruti
F. Petrelli
Publication date: 01-06-2020
Publisher: Springer International Publishing
Keywords: Melanoma
Melanoma
Published in: Clinical and Translational Oncology / Issue 6/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-019-02207-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Backgroud

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2020

Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis

Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes

Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies

Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer

Ethical commitment of Spanish oncologists to patients with prostate cancer: reflections on the statements of the new ASTRO/AUA guideline (2019 guideline amendment)

Treatment of radiation-induced myelopathy with bevacizumab

Keynote webinar | Spotlight on antibody–drug conjugates in cancer